Neurogene
Efsevia (Effie) Albanis has over two decades of experience in the medical and pharmaceutical industries. Efsevia (Effie) currently serves as the Chief Medical Officer at Neurogene Inc., a position they have held since June 2018.
Prior to their current role, Albanis worked at Mount Sinai School of Medicine as an Assistant Clinical Professor of Medicine from 2000 onwards.
In addition, Albanis also established their own consulting firm, Effie Albanis Consulting, LLC, in 2012 where they serve as the Principal.
Efsevia (Effie) has held various leadership positions at pharmaceutical companies including Intercept Pharmaceuticals, where they held the roles of Executive Director of Medical Affairs, Global NASH Physician, Executive Director of Strategy, and Senior Director of Strategy from 2014 to 2017.
Before their time at Intercept Pharmaceuticals, Albanis served as the Director of Medical Affairs at Gilead Sciences in 2012, Director of Medical Affairs at Pharmasset, Inc. from 2008 to 2012, and Director of Medical Affairs at Novartis from 2006 to 2008.
From 1990 to 1994, Efsevia (Effie) Albanis attended the Icahn School of Medicine at Mount Sinai. Efsevia (Effie) obtained a Doctor of Medicine (MD) degree during this period. No specific field of study information is provided.
This person is not in any teams
Neurogene
Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring to patients therapies that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy.